USANA Health Sciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2011 (52 weeks); filed March 14, 2012. Although the request metadata says “2010 Q4,” this filing reports fiscal 2011 and includes quarterly results for 2011. It is not a standalone 2010 Q4 report.
Business context
USANA develops and manufactures nutritional and personal-care products sold through independent direct-selling Associates and Preferred Customers. It operated in 15 markets and generated 74.6% of 2011 net sales outside the United States. At year-end, it reported 222,000 active Associates and 64,000 active Preferred Customers. Asia Pacific contributed 59.4% of sales, up from 53.2% in 2010; North America contributed 40.6%.
Key financial results
| Metric | FY2010 | FY2011 |
|---|---|---|
| Net sales | $517.6 million | $581.9 million |
| Gross profit | $422.2 million; 81.6% margin | $480.2 million; 82.5% margin |
| Operating earnings | $68.2 million; 13.3% margin | $77.3 million; 13.2% margin |
| Net earnings | $45.7 million; 8.8% margin | $50.8 million; 8.6% margin |
| Diluted EPS | $2.86 | $3.26 |
| Operating cash flow | $66.1 million | $70.1 million |
| Capital expenditures | $4.2 million | $10.6 million |
For Q4 2011, net sales were $145.9 million, net earnings were $13.2 million, and diluted EPS was $0.87. The company reported cash and cash equivalents of $50.4 million, working capital of $46.4 million, and total assets of $244.5 million at year-end. It had no outstanding debt; its $60 million credit facility runs to April 2016. The filing reports no cash dividends.
Changes versus the prior year
- Sales rose 12.4% year over year; management estimated a $15.0 million favorable foreign-exchange contribution, leaving 9.5% growth excluding currency effects.
- Asia Pacific sales grew 25.4%, led by Greater China, which rose 34.5% to $204.8 million. North America sales fell 2.4% to $236.4 million.
- Active Associates declined 2.6% to 222,000; North American Associates fell 9.3%. Active Preferred Customers declined 8.6% to 64,000.
- Gross margin improved from 81.6% to 82.5%, helped by currency, freight costs, pricing and sales leverage. Associate incentives rose to 45.7% of sales from 45.0%; SG&A rose to 23.6% from 23.3%. Operating margin edged down to 13.2% from 13.3%.
- Operating cash flow increased by $4.0 million. The company repurchased 1.1 million shares for $33.5 million, reducing shares outstanding and supporting EPS growth.
Outlook, commentary and risks
- Management expected 2012 gross margin to be modestly lower due to raw-material cost increases and a stronger U.S. dollar; Associate incentives were expected to be modestly lower following pricing and commission changes.
- Management expected SG&A to increase in absolute and relative terms as it invested in North American growth and opened France, Belgium and Thailand. Capital expenditures were projected at $7–10 million for 2012. Management believed cash, operating cash flow and available credit would cover foreseeable ordinary needs.
- The North America recovery plan requires upfront investment; management said successful execution could produce results as early as Q4 2012. The company also continued integrating BabyCare in China and seeking additional provincial direct-selling licenses.
- Hong Kong generated 26.9% of sales. Management expected 2012 Hong Kong sales to be closer to approximately $35 million per quarter, versus unusually strong 2011 results affected by promotions, pricing and timing items. China growth depends on product registrations, licensing and acceptance of its separate compensation model.
- Key risks include reliance on independent Associates and retention, continued North American weakness, possible Hong Kong declines, China regulatory limits, foreign-exchange exposure, product and advertising regulation, and competition. Currency benefited 2011 sales, but management warned exchange rates could weigh on 2012 comparisons.
- The company disclosed routine litigation and disputes; management assessed the likelihood of a material adverse outcome as remote. The Athlete Guarantee program is uninsured, though management judged the chance of a liability less than remote. No current legal proceeding was expected to materially harm the business.
- The company revised certain prior balance-sheet and comprehensive-income presentation amounts for deferred taxes and currency translation of acquired China intangibles; it stated the revisions were not material and did not affect earnings or EPS. Goodwill testing found no impairment. PwC issued an unqualified audit opinion and reported effective internal control over financial reporting.
Important facts for investors to verify
- Whether North American Associate and customer declines stabilize, and whether the 2012 growth program generates sales sufficient to justify higher spending.
- Whether China secures additional direct-selling licenses and product registrations, and whether growth offsets any normalization or decline in Hong Kong.
- Whether gross-margin pressure, Associate incentive payouts and SG&A trends develop as management forecast, including the effect of currency and raw-material costs.
- Whether cash generation and liquidity remain adequate while the company funds expansion, capital spending and repurchases; review the credit-facility covenants requiring adjusted EBITDA of at least $60 million and funded debt/adjusted EBITDA no greater than 2.0 to 1.0.
- The detailed impact of the prior-period financial-statement revisions, tax positions, and China-related goodwill and intangible-asset estimates.